{"doc_id": "33378989", "type of study": "Therapy", "title": "", "abstract": "Tocilizumab combined with favipiravir in the treatment of COVID-19: A multicenter trial in a small sample size.\nSince December 2019, COVID-19 has spread to almost every corner of the world.\nIn theory, tocilizumab and favipiravir are considered to be reliable drugs for the treatment of COVID-19 with elevated IL-6.\nWe aimed to assess the efficacy and safety of tocilizumab combined with favipiravir in patients with COVID-19.\nThis was a multicenter trial in adults with COVID-19.\nPatients were randomly assigned (3:1:1) to a 14-day combination of favipiravir combined with tocilizumab (combination group), favipiravir, and tocilizumab.\nThe primary outcome was the cumulative lung lesion remission rate (lung CT examination indicated absorption of lung inflammation).\nBetween Feb 2 and March 15, 2020, 26 patients were recruited; 14 were randomly assigned to the combination group, 7 were assigned to the favipiravir group and 5 were assigned to the tocilizumab group.\nThe cumulative lung lesion remission rate at day 14 was significantly higher in combination group as compared with favipiravir group (P\u2009=\u20090.019, HR 2.66 95 % CI [1.08-6.53]).\nAnd there was also a significant difference between tocilizumab and favipivavir (P\u2009=\u20090.034, HR 3.16, 95 % CI 0.62-16.10).\nIn addition, there was no significant difference between the combination group and the tocilizumab group (P\u2009=\u20090.575, HR 1.28 95 %CI 0.39-4.23).\nFurthermore, combined therapy can also significantly relieve clinical symptoms and help blood routine to return to normal.\nNo serious adverse events were reported.\nTocilizumab combined with or without favipiravir can effectively improve the pulmonary inflammation of COVID-19 patients and inhibit the deterioration of the disease.\nCopyright \u00a9 2020.\nPublished by Elsevier Masson SAS.\n", "Evidence Map": {"Enrollment": [{"term": "COVID-19", "negation": "affirmed", "UMLS": {}, "start": 58, "end": 66}, {"term": "COVID-19", "negation": "affirmed", "UMLS": {}, "start": 101, "end": 109}, {"term": "adults", "negation": "affirmed", "UMLS": {}, "start": 32, "end": 38}, {"term": "COVID-19", "negation": "affirmed", "UMLS": {}, "start": 44, "end": 52}, {"term": "COVID-19", "negation": "affirmed", "UMLS": {}, "start": 103, "end": 111}], "Comparison Results": [], "Study Arm 1 Results": [], "Study Arm 2 Results": [], "Hypothesis": []}, "Sentence-level breakdown": [{"Section": "TITLE", "Text": "Tocilizumab combined with favipiravir in the treatment of COVID-19 : A multicenter trial in a small sample size .", "Evidence Elements": {"Participant": [{"term": "COVID-19", "negation": "affirmed", "UMLS": {}, "start": 58, "end": 66}], "Intervention": [{"term": "Tocilizumab combined with favipiravir", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 37, "has_chemical": [{"text": "tocilizumab", "maps_to": "C1609165:tocilizumab", "start": 0, "end": 11}, {"text": "favipiravir", "maps_to": "C1138226:favipiravir", "start": 26, "end": 37}], "has_relation": "combined_with (C1609165<->C1138226)"}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "BACKGROUND", "Text": "Since December 2019 , COVID-19 has spread to almost every corner of the world .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "BACKGROUND", "Text": "In theory , tocilizumab and favipiravir are considered to be reliable drugs for the treatment of COVID-19 with elevated IL-6 .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "BACKGROUND", "Text": "We aimed to assess the efficacy and safety of tocilizumab combined with favipiravir in patients with COVID-19 .", "Evidence Elements": {"Participant": [{"term": "COVID-19", "negation": "affirmed", "UMLS": {}, "start": 101, "end": 109}], "Intervention": [{"term": "tocilizumab combined with favipiravir", "negation": "affirmed", "UMLS": {}, "start": 46, "end": 83, "has_chemical": [{"text": "tocilizumab", "maps_to": "C1609165:tocilizumab", "start": 0, "end": 11}, {"text": "favipiravir", "maps_to": "C1138226:favipiravir", "start": 26, "end": 37}], "has_relation": "combined_with (C1609165<->C1138226)"}], "Outcome": [{"term": "efficacy", "negation": "affirmed", "UMLS": {}, "start": 23, "end": 31}, {"term": "safety", "negation": "affirmed", "UMLS": {}, "start": 36, "end": 42}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "This was a multicenter trial in adults with COVID-19 .", "Evidence Elements": {"Participant": [{"term": "adults", "negation": "affirmed", "UMLS": {}, "start": 32, "end": 38}, {"term": "COVID-19", "negation": "affirmed", "UMLS": {}, "start": 44, "end": 52}], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "Patients were randomly assigned (3:1:1) to a 14-day combination of favipiravir combined with tocilizumab ( combination group ) , favipiravir , and tocilizumab .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "combination of favipiravir combined with tocilizumab", "negation": "affirmed", "UMLS": {}, "start": 52, "end": 104, "has_chemical": [{"text": "favipiravir", "maps_to": "C1138226:favipiravir", "start": 15, "end": 26}, {"text": "tocilizumab", "maps_to": "C1609165:tocilizumab", "start": 41, "end": 52}], "has_relation": "combined_with (C1138226<->C1609165)"}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "The primary outcome was the cumulative lung lesion remission rate ( lung CT examination indicated absorption of lung inflammation ) .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "cumulative lung lesion remission rate", "negation": "affirmed", "UMLS": {}, "start": 28, "end": 65}, {"term": "absorption of lung", "negation": "affirmed", "UMLS": {}, "start": 98, "end": 116}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "RESULTS", "Text": "Between Feb 2 and March 15, 2020, 26 patients were recruited; 14 were randomly assigned to the combination group, 7 were assigned to the favipiravir group and 5 were assigned to the tocilizumab group .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "combination", "negation": "affirmed", "UMLS": {}, "start": 95, "end": 106, "has_relation": "N/A"}, {"term": "favipiravir", "negation": "affirmed", "UMLS": {}, "start": 137, "end": 148, "has_chemical": [{"text": "favipiravir", "maps_to": "C1138226:favipiravir", "start": 0, "end": 11}], "has_relation": "N/A"}, {"term": "tocilizumab", "negation": "affirmed", "UMLS": {}, "start": 182, "end": 193, "has_chemical": [{"text": "tocilizumab", "maps_to": "C1609165:tocilizumab", "start": 0, "end": 11}], "has_relation": "N/A"}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "RESULTS", "Text": "The cumulative lung lesion remission rate at day 14 was significantly higher in combination group as compared with favipiravir group ( P = 0.019 , HR 2.66 95 % CI [ 1.08-6.53 ] ) .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "combination", "negation": "affirmed", "UMLS": {}, "start": 80, "end": 91, "has_relation": "N/A"}, {"term": "favipiravir", "negation": "affirmed", "UMLS": {}, "start": 115, "end": 126, "has_chemical": [{"text": "favipiravir", "maps_to": "C1138226:favipiravir", "start": 0, "end": 11}], "has_relation": "N/A"}], "Outcome": [{"term": "cumulative lung lesion remission rate at day 14", "negation": "affirmed", "UMLS": {}, "start": 4, "end": 51}], "Observation": [{"term": "significantly higher", "negation": "affirmed", "UMLS": {}, "start": 56, "end": 76}], "Count": []}, "Evidence Propositions": [{"Intervention": [{"term": "combination", "has_relation": "N/A"}, {"term": "favipiravir", "has_chemical": [{"text": "favipiravir", "maps_to": "C1138226:favipiravir", "start": 0, "end": 11}], "has_relation": "N/A"}], "Observation": "significantly higher", "Outcome": "cumulative lung lesion remission rate at day 14", "Count": ""}]}, {"Section": "RESULTS", "Text": "And there was also a significant difference between tocilizumab and favipivavir ( P = 0.034 , HR 3.16 , 95 % CI 0.62-16.10 ) .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "tocilizumab", "negation": "affirmed", "UMLS": {}, "start": 52, "end": 63, "has_chemical": [{"text": "tocilizumab", "maps_to": "C1609165:tocilizumab", "start": 0, "end": 11}], "has_relation": "N/A"}, {"term": "favipivavir", "negation": "affirmed", "UMLS": {}, "start": 68, "end": 79, "has_relation": "N/A"}], "Outcome": [], "Observation": [{"term": "significant difference", "negation": "affirmed", "UMLS": {}, "start": 21, "end": 43}], "Count": []}, "Evidence Propositions": [{"Intervention": [{"term": "tocilizumab", "has_chemical": [{"text": "tocilizumab", "maps_to": "C1609165:tocilizumab", "start": 0, "end": 11}], "has_relation": "N/A"}, {"term": "favipivavir", "has_relation": "N/A"}], "Observation": "significant difference", "Outcome": "", "Count": ""}]}, {"Section": "RESULTS", "Text": "In addition , there was no significant difference between the combination group and the tocilizumab group ( P = 0.575 , HR 1.28 95 % CI 0.39-4.23 ) .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "combination", "negation": "negated", "UMLS": {}, "start": 62, "end": 73, "has_relation": "N/A"}, {"term": "tocilizumab", "negation": "negated", "UMLS": {}, "start": 88, "end": 99, "has_chemical": [{"text": "tocilizumab", "maps_to": "C1609165:tocilizumab", "start": 0, "end": 11}], "has_relation": "N/A"}], "Outcome": [], "Observation": [{"term": "significant difference", "negation": "affirmed", "UMLS": {}, "start": 27, "end": 49}], "Count": []}, "Evidence Propositions": [{"Intervention": [{"term": "combination", "has_relation": "N/A"}, {"term": "tocilizumab", "has_chemical": [{"text": "tocilizumab", "maps_to": "C1609165:tocilizumab", "start": 0, "end": 11}], "has_relation": "N/A"}], "Observation": "significant difference", "Outcome": "", "Count": ""}]}, {"Section": "RESULTS", "Text": "Furthermore , combined therapy can also significantly relieve clinical symptoms and help blood routine to return to normal .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "combined therapy", "negation": "affirmed", "UMLS": {}, "start": 14, "end": 30, "has_procedure": [{"text": "combined therapy", "maps_to": "C0033972:combined therapy", "start": 0, "end": 16}], "has_relation": "N/A"}], "Outcome": [{"term": "clinical symptoms", "negation": "affirmed", "UMLS": {}, "start": 62, "end": 79}, {"term": "blood routine to return to", "negation": "affirmed", "UMLS": {}, "start": 89, "end": 115}], "Observation": [{"term": "significantly relieve", "negation": "affirmed", "UMLS": {}, "start": 40, "end": 61}], "Count": []}, "Evidence Propositions": []}, {"Section": "RESULTS", "Text": "No serious adverse events were reported .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "serious adverse events", "negation": "negated", "UMLS": {}, "start": 3, "end": 25}], "Observation": [], "Count": [{"term": "No", "negation": "negated", "UMLS": {}, "start": 0, "end": 2}]}, "Evidence Propositions": []}, {"Section": "CONCLUSION", "Text": "Tocilizumab combined with or without favipiravir can effectively improve the pulmonary inflammation of COVID-19 patients and inhibit the deterioration of the disease .", "Evidence Elements": {"Participant": [{"term": "COVID-19", "negation": "affirmed", "UMLS": {}, "start": 103, "end": 111}], "Intervention": [{"term": "Tocilizumab combined with or without favipiravir", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 48, "has_chemical": [{"text": "tocilizumab", "maps_to": "C1609165:tocilizumab", "start": 0, "end": 11}, {"text": "favipiravir", "maps_to": "C1138226:favipiravir", "start": 37, "end": 48, "has_negation": ["without"]}], "has_relation": "combined_with (C1609165<->C1138226)"}], "Outcome": [{"term": "pulmonary inflammation", "negation": "affirmed", "UMLS": {}, "start": 77, "end": 99}, {"term": "deterioration of the disease", "negation": "affirmed", "UMLS": {}, "start": 137, "end": 165}], "Observation": [{"term": "improve", "negation": "affirmed", "UMLS": {}, "start": 65, "end": 72}, {"term": "inhibit", "negation": "affirmed", "UMLS": {}, "start": 125, "end": 132}], "Count": []}, "Evidence Propositions": [{"Intervention": {"term": "Tocilizumab combined with or without favipiravir", "has_chemical": [{"text": "tocilizumab", "maps_to": "C1609165:tocilizumab", "start": 0, "end": 11}, {"text": "favipiravir", "maps_to": "C1138226:favipiravir", "start": 37, "end": 48, "has_negation": ["without"]}], "has_relation": "combined_with (C1609165<->C1138226)"}, "Observation": "improve", "Outcome": "pulmonary inflammation", "Count": ""}, {"Intervention": {"term": "Tocilizumab combined with or without favipiravir", "has_chemical": [{"text": "tocilizumab", "maps_to": "C1609165:tocilizumab", "start": 0, "end": 11}, {"text": "favipiravir", "maps_to": "C1138226:favipiravir", "start": 37, "end": 48, "has_negation": ["without"]}], "has_relation": "combined_with (C1609165<->C1138226)"}, "Observation": "inhibit", "Outcome": "deterioration of the disease", "Count": ""}]}, {"Section": "UNKNOWN", "Text": "Copyright \u00a9 2020 .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Published by Elsevier Masson SAS .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}]}